BRIEF

on Bausch Health Companies Inc. (NASDAQ:BHC)

Bausch Health Acknowledges XIFAXAN's Selection for Medicare Negotiation

Stock price chart of Bausch Health Companies Inc. (EBR:BHC) showing fluctuations.

Bausch Health Companies Inc. and its division, Salix Pharmaceuticals, have recognized XIFAXAN® (rifaximin) 550 mg tablets' selection by the Centers for Medicare and Medicaid Services (CMS) for the Inflation Reduction Act's Drug Price Negotiation program. This inclusion will affect pricing beginning in 2027.

The company anticipates engaging in open discussions with CMS to present the value of XIFAXAN® to the healthcare system. Recommendations from significant liver disease associations, AASLD and EASL, support XIFAXAN®'s utilization, acknowledging it with the highest recommendation grade.

Bausch Health is committed to advocating for patient access to essential medications and encourages ongoing innovation in the healthcare sector.

R. H.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Bausch Health Companies Inc. news